Implementing Quality Measures for Inflammatory Bowel Disease

被引：19

作者：

Ahmed S. ^{[1
]}

Siegel C.A. ^{[2
]}

Melmed G.Y. ^{[1
]}

机构：

[1] Cedars-Sinai Medical Center, 8730 Alden Dr 2E, Los Angeles, 90048, CA

[2] Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Lebanon, NH

来源：

Current Gastroenterology Reports | 2015年 / 17卷 / 4期

基金：

美国国家卫生研究院; 美国医疗保健研究与质量局;

关键词：

Crohn disease; Improvement; Inflammatory bowel disease; Quality; Ulcerative colitis;

D O I：

10.1007/s11894-015-0437-1

中图分类号：

学科分类号：

摘要：

Variation in care for inflammatory bowel disease (IBD) is present across multiple aspects of IBD management, suggesting overall poor quality of care. Quality indicators are intended to provide clear, measurable processes and outcomes of quality care. Initial sets of process and outcome measures have been developed to address areas of inconsistent care and to allow for standardized measurement of outcomes. Measures developed by the Crohn’s and Colitis Foundation of America (CCFA) are intended to provide measurable standards for improvement in care. These measure sets will warrant updates overtime to best represent gaps in IBD management. Practically, implementation of quality measures may depend on the care setting and whether quality measurement and improvement can be incorporated into workflows and electronic medical records. Collaborative networks, utilization of care pathways, and standardized treatment algorithms may represent avenues for wide-scale implementation of quality improvement. Implementation efforts should assess the impact on outcomes in order to identify successful models for improvement in IBD care. © 2015, Springer Science+Business Media New York.

引用

页数：5

共 49 条

[1]

Institute of Medicine, To err is human: building a safer health system, (2000)

[2]

Institute of Medicine, Crossing the quality chasm: a new health system for the 21st century, (2001)

[3]

Berwick D.M., Nolan T.W., Whittington J., The triple aim: care, health, and cost, Health Aff (Millwood), 27, pp. 759-769, (2008)

[4]

de Jonge V., Sint Nicolaas J., van Leerdam M.E., Et al., Overview of the quality assurance movement in health care, Best Pract Res Clin Gastroenterol, 25, pp. 337-347, (2011)

[5]

Singh A.K., Szczech L., Tang K.L., Et al., Correction of anemia with epoetin alfa in chronic kidney disease, N Engl J Med, 355, pp. 2085-2098, (2006)

[6]

UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ, 317, pp. 703-713, (1998)

[7]

Serruys P.W., Morice M.C., Kappetein A.P., Et al., Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease, N Engl J Med, 360, pp. 961-972, (2009)

[8]

Chen Z.M., Jiang L.X., Chen Y.P., Et al., Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet, 366, pp. 1607-1621, (2005)

[9]

Chen Z.M., Pan H.C., Chen Y.P., Et al., Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet, 366, pp. 1622-1632, (2005)

[10]

Berwick D.M., Disseminating innovations in health care, Jama, 289, pp. 1969-1975, (2003)

← 1 2 3 4 5 →